EP0619840A1 - Vaccin contre la pseudorage - Google Patents

Vaccin contre la pseudorage

Info

Publication number
EP0619840A1
EP0619840A1 EP93922915A EP93922915A EP0619840A1 EP 0619840 A1 EP0619840 A1 EP 0619840A1 EP 93922915 A EP93922915 A EP 93922915A EP 93922915 A EP93922915 A EP 93922915A EP 0619840 A1 EP0619840 A1 EP 0619840A1
Authority
EP
European Patent Office
Prior art keywords
prv
ala
mutant
mutation
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93922915A
Other languages
German (de)
English (en)
Inventor
Thomas Christoph Mettenleiter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Priority to EP93922915A priority Critical patent/EP0619840A1/fr
Publication of EP0619840A1 publication Critical patent/EP0619840A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention is concerned with a pseudorabies virus (PrV) mutant, a recombinant DNA molecule comprising PrV DNA, a host cell transformed with said recombinant DNA molecule, a cell culture infected with the mutant, a vaccine derived from the PrV mutant as well as a method to distinguish whether an animal has been vaccinated or is infected with naturally-occurring Pseudorabies virus.
  • PrV pseudorabies virus
  • Pseudorabies virus is a member of the herpes virus group. It is the causative agent of Aujeszky's disease which induces serious economic losses especially among piglets in swine breeding farms and leads to latent infection in older animals.
  • the predominant visible feature of PrV infection is intense pruritus generally resulting in host mutilation of the involved area. Violent excitement, fits and paralysis, all symptoms of encephalomyelitis, precede death which usually occurs within a few days following onset of clinical signs.
  • Vaccination only will stimulate production of antibodies to the limited spectrum of antigens present in the vaccine.
  • the vaccinated animal has antibodies only to the antigens contained in the vaccine while an animal infected with the wild-type virus would have antibodies against a wider range of antigens.
  • Live modified virus vaccines have the advantage that they comprise more antigens and that thus a stronger immune response can be obtained. The chances are that uncontrolled mutations occur during passaging, resulting in populations of virus particles which are heterogeneous in virulence and immunizing properties. More important it is well known that such traditional attenuated viruses can revert to virulence resulting in disease of the vaccinated animals and the possible spread of the pathogen to other animals.
  • Herpes viruses of the PrV type contain in their core a double-stranded DNA molecule with a molecular weight of about 90 x 106 daltons (D) , separated by inverted repeats into a long and a short unique region UL and US, respectively (Sheldric, P. and N. Berthelot, 1975. Inverted repetitions in the chromosome of herpes simplex virus. Cold Spring Harbor Symp. Quant. Biol. 39:667-678).
  • herpes virus genome encodes a minimum of 75 open reading frames (ORFs), of which 69 map in the UL and US sequences (McGeoch, D.J. , M.A. Dalrymple, A.J. Davison, A. Dolan, M.C. Frame, D. McNab, L.J. Perry, J.E. Scott and P. Taylor, 1988.
  • ORFs open reading frames
  • the complete DNA sequence of the long unique region in the genome of herpes simplex virus type l. J. Gen. Virol. 69:1531-1574; Wagner, E.K., 1984. Individual HSV transcripts. Characterization of specific genes, p. 45-104. In: B. Roizman (ed.), The Herpesviruses, vol. 3, Plenum Press, New York.).
  • the genome of the herpes viruses is commonly referred to in terms of restriction enzyme fragments.
  • pseudorabies virus recently the sequence of the Bam HI fragments 11 and 16 has been published (Klupp, B.G. and T.C. Mettenleiter, 1991. Sequence and expression of the glycoprotein gH gene of Pseudorabies Virus. Virology 182:732-741).
  • the PrV mutant offers the possibility of a multivalent vaccine without the risk of adverse mutual interference of different antigenic components.
  • An other object of the present invention is to provide a PrV vaccine virus which is distinguishable from any field strain. It is important to discriminate between animals vaccinated with a PrV vaccine and those infected with a wild type virus so as to be able to take appropriate measures to reduce spreading of a virulent virus.
  • PrV mutant comprising a mutation obtained by recombinant DNA techniques in a part of the PrV genome which spans the region comprising the DNA sequences of the open reading frame (ORF) encoding the polypeptide as shown in SEQ ID NO:2.
  • polypeptide refers to a molecular chain of amino acids, does not refer to a specific length of the product and if required can be modified in vivo or in vitro, for example by glycosylation, amidation, carboxylation or phosphorylation; thu& inter alia peptides, oligopeptides and proteins are included within the definition of polypeptide.
  • a mutation is understood to be a change of the genetic information by recombinant DNA techniques in the above-mentioned region with respect to the genetic information present in this region of the genome of naturally occurring PrV.
  • the mutation is in particular, a nucleic acid substitution, deletion, insertion or inversion, or a combination thereof resulting in a PrV mutant which fails to produce the antigenic or functional polypeptide, shown in SEQ ID NO:2, or in a PrV mutant which contains an inserted heterologous nucleic sequence.
  • the mutation may result also in the production of a polypeptide deviating from the above- mentioned polypeptide of SEQ ID NO:2 displaying altered antigenic or functional properties.
  • the mutation is a deletion and/or an insertion and/or one or more nucleotide substitutions.
  • the preferred substitution herein is a combination of substitutions such that the codon encoding His at position 37 is changed to a codon encoding Arg, the codon encoding Glu at position 355 is changed to a codon encoding Asp, and the codon encoding Val at position 375 is changed to a codon encoding Ala.
  • a mutation can occur in the control elements for the ORF localized in the intergenic sequence, which may result in a failure of the expression of the polypeptide.
  • the deletion in the genome of the PrV mutant may comprise a whole ORF.
  • PrV mutants according to the invention can also be obtained by inserting a nucleic acid sequence into the genome thereby preventing or altering the expression of the polypeptide shown in SEQ ID NO:2.
  • the BamHI 4 fragment of the PrV virus comprises the nucleic acid sequence spanning 9382 nucleotide base pairs (GenBank Data Library Accession No. L00676). This sequence comprises inter alia two open reading frames: a. ORF-1 localized between basepair no. 760 and basepair no. 2333, which in opposite direction codes for the polypeptide shown in SEQ ID NO:2, having 525 amino acids; b. ORF-2 localized between basepair no. 2440 and basepair no. 2921, which in this direction codes for a polypeptide, having 161 amino acids.
  • the (insertion-)region referred to in the present invention (SEQ ID NO:l) has not been identified previously within the PRV genome. Surprisingly, it has been found that a mutation is allowable in this region without disrupting essential functions of the PrV.
  • nucleotide substitution A 110 to G il ⁇ ' A 1 06 5 ⁇ ° c 1 06 5 and T 11 4 to c ll 24 resulting in a change of the respective codons results in the expression of a polypeptide having functional characteristics deviating from those of the polypeptide shown in SEQ ID NO:2 such that the PrV mutant thus obtained is less virulent than the parent virus.
  • a PrV mutant has a mutation in the part of the PrV genome having the nucleic acid sequence as shown in SEQ ID NO:l.
  • PrV mutant according to the invention is derived from the strain Ka
  • any PrV strain can be used to prepare the PrV mutant, such as NIA-3, RICE, 75V19 or Phylaxia.
  • PrV mutants can be provided with an insertion in the DNA sequence defined herein.
  • such an insert is merely meant to prohibit or alter the expression of the polypeptide shown in SEQ ID NO:2. This can for instance be done by insertion of a number of basepairs which is not divisable by three, thereby shifting the reading frame, or by inserting a sequence containing a stop codon, or by inserting a non-sense sequence.
  • the insert comprises a heterologous nucleic acid sequence encoding a polypeptide.
  • heterologous nucleic acid sequence is incorporated in a permissive position or region of the genomic PrV sequence, i.e. a position or region which can be used for the incorporation of a heterologous sequence without disrupting essential functions of PrV such as those necessary for infection or replication.
  • a region is called an insertion-region.
  • PrV mutant denotes infective virus which has been genetically modified by incorporation into the virus genome of a heterologous nucleic acid sequence, i.e. DNA which comprises a nucleic acid sequence not identical to the nucleic acid sequence of a gene naturally present in PrV.
  • the recombinant PrV mutant On infection of a cell by the recombinant PrV mutant, it may express the heterologous gene in the form of a heterologous polypeptide.
  • the insertion-region referred to in the present invention has not been identified previously within the PrV genome. Surprisingly, it has been found that a mutation such as the incorporation of heterologous DNA is allowable in this region without disrupting essential functions of the PrV.
  • the insertion-region essentially defined above characterizes the localization of a region within the PrV genome which can be used to introduce a deletion or to incorporate a heterologous nucleic acid sequence, if desired after deleting DNA sequences from this region, or can be used to introduce other mutations in said region.
  • heterologous nucleic acid sequence to be incorporated into the PRV genome according to the present invention can be derived from any source, e.g. viral, prokaryotic, eukaryotic or synthetic.
  • Said heterologous nucleic acid sequence can be derived from a pathogen, preferably a porcine pathogen, which after insertion into the PrV genome can be applied to induce immunity against disease.
  • nucleic acid sequences encoding a polypeptide of parvovirus, enteropathogenic Escherichia coli, foot and mouth disease virus, Bordetella bronchiseptica, Mycoplasma hyopneumoniae, Pasteurella multocida or Streptococcus suis are contemplated for incorporation into the insertion- region of the PRV genome.
  • heteronucleic acid sequences encoding polypeptides for pharmaceutical or diagnostic applications in particular immuno-modulators such as lymphokines, interferons or cytokines, or marker enzymes as ⁇ -galactosidase or superoxidedismutase may be incorporated into said insertion-region.
  • immuno-modulators such as lymphokines, interferons or cytokines, or marker enzymes as ⁇ -galactosidase or superoxidedismutase
  • An essential requirement for the expression of the heterologous nucleic acid sequence in a recombinant PrV mutant is an adequate promoter operably linked to the heterologous nucleic acid sequence. It is obvious to those skilled in the art that the choice of a promoter extends to any eukaryotic, prokaryotic or viral promoter capable of directing gene transcription in cells infected by the recombinant PrV, e.g.
  • promoters of the retroviral long terminal repeat (Gorman et al., Proc. Natl. Acad. Sci. USA 79, 6777-6781, 1982), the SV40 promoter (Mulligan and Berg, Science 209, 1422-1427, 1980) or the cytomegalovirus immediate early promoter (Schaffner et al., Cell 41, 521-530, 1985).
  • the technique of in vivo homologous recombination can be used to introduce a nucleic acid sequence carrying the mutated sequence into the PrV genome.
  • the first step of this technique includes the construction of a recombinant DNA molecule for recombination with PrV genomic DNA.
  • a recombinant DNA molecule may be derived from any suitable plasmid, cosmid or phage, plasraids being most preferred, and comprises a fragment of PrV DNA containing DNA of the part of the PrV genome as defined above.
  • a mutation can be introduced in this fragment by deletion or by insertion of a heterologous nucleic acid sequence, optionally in combination with controlling sequences.
  • the DNA sequence of the part of the PrV genome as defined above preferably is flanked by PrV nucleic acid sequences which should be of appropriate length, e.g. 50-3000 bp, as to allow in vivo homologous recombination with the viral PrV genome to occur.
  • the recombinant DNA molecule obtained in this way is suitable for introducing the mutation into the PrV genome.
  • a recombinant DNA molecule can be made which contains two or more different heterologous nucleic acid sequences derived from the same or different pathogens, said sequences being incorporated into insertion-region sequences which are flanked by PrV nucleic acid sequences.
  • Such a recombinant DNA molecule can be employed to produce recombinant PrV which expresses two or more different antigenic polypeptides to provide a multivalent vaccine.
  • cells e.g. swine kidney cells or VERO cells can be transfected with PrV DNA or infected with a wild type PrV in the presence of the recombinant DNA molecule as described above whereby recombination occurs between the sequences in the recombinant DNA molecule and the corresponding sequences in the PrV genome.
  • Recombination can also be brought about by co- transfecting the cells with a nucleic acid sequence containing the mutation sequence flanked by appropriate flanking PrV sequences without plasmid sequences.
  • Recombinant viral progeny is thereafter produced in cell culture and can be selected for example genotypically or phenotypically, e.g. by hybridization or by detecting enzyme activity encoded by a gene co-integrated along with nucleic acid sequence comprising the mutation. Another possibility is the detection of the absence of the polypeptide for which the nucleic acid sequence in which the mutation was localized was coding. In the same way the presence of the polypeptide coded for by an inserted heterologous nucleic acid sequence can be detected.
  • Recombinant virus can also be selected positively based on resistance to compounds such as neomycine, gentamycine or mycophenolic acid.
  • the selected recombinant PrV can be cultured on a large scale in cell culture after which recombinant PrV containing material or heterologous polypeptides expressed by said PrV can be collected thereof.
  • Host cells transformed with a recombinant DNA molecule as defined above also form part of the invention.
  • Another part of the invention is formed by cell cultures infected with PrV mutants according to the invention.
  • a live PrV mutant according to the present invention can be used to vaccinate animals, particularly pigs.
  • a PrV mutant in which the mutation is a deletion preferably no expression of the PrV polypeptide as shown in SEQ ID NO:2 is established while still replication of the PrV mutant in the inoculated host takes place.
  • a PrV mutant expressing one or more different heterologous polypeptides of specific pathogens it is preferably followed by replication of the recombinant PrV within the inoculated host, expressing in vivo the heterologous polypeptide along with the PrV polypeptides.
  • the polypeptides expressed in the inoculated host will then elicit an immune response against both PrV and the specific pathogen.
  • the heterologous polypeptide derived from the specific pathogen can stimulate a protective immune response, then the animal inoculated with a recombinant PrV mutant according to the invention will be immune to subsequent infection by that pathogen as well as to infection by PrV.
  • a heterologous nucleic acid sequence incorporated into the insertion-region of the PrV genome according to the invention may be continuously expressed in vivo, providing a solid, safe and long-lasting immunity to a pathogen.
  • a PrV mutant according to the invention containing and expressing one or more different heterologous polypeptides can serve as a monovalent 01 multivalent vaccine.
  • the PrV mutant according to the present invention can be grown on a cell culture of porcine origin or on VERO cells.
  • the viruses thus grown can be harvested by collecting the tissue cell culture fluids and/or cells.
  • the live vaccine may be prepared in the form of a suspension or may be lyophilized.
  • the vaccine may contain a pharmaceutically acceptable carrier or diluent.
  • Examples of pharmaceutically acceptable carriers or diluents useful in the present invention include stabilizers such as SPGA, carbohydrates (e.g. sorbitol, mannitol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, protein containing agents such as bovine serum or skimmed milk and buffers (e.g. phosphate buffer).
  • stabilizers such as SPGA
  • carbohydrates e.g. sorbitol, mannitol, starch, sucrose, glucose, dextran
  • proteins such as albumin or casein
  • protein containing agents such as bovine serum or skimmed milk
  • buffers e.g. phosphate buffer
  • one or more compounds having adjuvant activity may be added to the vaccine.
  • Suitable adjuvants are for example aluminium hydroxide, phosphate or oxide, oil-emulsions (e.g. of Bayol F(R) or Marcol 52(R), saponins or vitamin-E solubilisate.
  • the useful dosage to be administered will vary depending on the age, weight and mode of administration.
  • a suitable dosage can be for example about 10 2 -10 7 pfu/animal.
  • PrV mutant according to the invention can also be used to prepare an inactivated vaccine.
  • the PrV mutant according to the presentation can be given inter alia intranasally, intradermally, subcutaneously or intramuscularly.
  • This can be achieved by culturing cells infected with said PrV mutant under conditions that promote expression of the heterologous polypeptide.
  • the heterologous polypeptide may then be purified with conventional techniques to a certain extent depending on its intended use and processed further into a preparation with immunizing, therapeutic or diagnostic activity.
  • the invention also provides a method for distinguishing an animal vaccinated with a vaccine of the present invention from an animal infected with naturally occurring PrV.
  • This method comprises analyzing a body fluid of the animal for the presence of antigens normally expressed in and circulating in the body fluid of an animal infected with a naturally- occurring PrV, identifying antigens which are present in the body fluid and correlating said antigens with antigens expressed in and circulating in the body fluid of an animal infected with a pseudorabies virus mutant of the invention.
  • the presence of antigens which are normally expressed in the animal by a naturally-occurring PrV is indicative for infection with PrV, while the presence of the same antigens with the exception of those no longer included in the PrV mutant of the invention is indicative of an animal vaccinated with the vaccine of the invention and not infected with a naturally-occurring pseudorabies virus.
  • Determining the presence and identification of the antigens can be done directly by the detection of the antigens in the body fluid or indirectly by the detection of antibodies in the body fluid which are specific for the antigens.
  • the discrimination between animals vaccinated with a vaccine which comprises the PrV mutant of the invention and animals infected by naturally occurring viruses can be accomplished by analyzing a body fluid for the presence of the polypeptide shown in SEQ ID "TO:2 and at least one other antigen normally expressed in an animal both by the PrV mutant and by a naturally-occurring PrV. Antigens or antibodies which are present in the body fluid are identified and the presence or absence of said antigens or polypeptides is determined.
  • testkit for distuinguishing the PrV mutant of the invention from naturally-occurring PrV mutants in the body fluid of an animal.
  • a testkit comprises a compound suitable for the detection of the polypeptide shown in SLQ ID NO:2, or antibodies against it, and a compound suitable for the detection of an antigen expressed by both the PrV mutant accoording to the invention and naturally-occurring PrV strains, or antibodies against said antigen.
  • Another test can be performed to determine if an animal is infected by a naturally-occurring PrV. In this case only a test on the presence of antigens from or antibodies against the polypeptide shown in SEQ ID NO:2 can show if an animal has been infected by a naturally-occurring PrV.
  • the virulent PRV strain Ka and mutant PRV strains were propagated and plaque-ourified in Madin Darby bovine kidney cells (MDBK, ATCC CCL 221) or in SK-6 porcine kidney cells.
  • the cells were maintained in Eagle minimal essential medium (MEM) with 10% newborn calf serum (Boehringer, Mannheim, FRG) and 100 units/ml penicillin and 100 ⁇ g/ml streptomycin.
  • MEM Eagle minimal essential medium
  • BHK baby hamster kidney
  • DMEM Dulbecco modified minimal essential medium
  • Virions were purified from the supernatant of infected cells (ca. 5 pfu/cell) by differential centrifugation and velocity sedimentation through 12 to 52% (w/v) sucrose gradient as recently described (Lukacs et al., 1985).
  • the virion band was aspirated, diluted with 0.2 M Tris- HC1, 5 mM EDTA, 0.15 M NaCl, and concentrated by pelleting in a SW27 rotor (Beckman) at 25.000 RPM, 4°C for one hour.
  • Bam HI fragment 4 of the wildtype pseudorabies virus strain Ka was subcloned as a 3.8 kb Bam Hi/Sal I fragment, a 2.7 kb Sal I fragment and a 2.9 kb Sal I fragment into a pBR322 derivative into which a multiple cloning site originating from bacteriophage M13mpl8 had been introduced.
  • the extreme left and right termini of the whole Bam HI-4 fragment were sequenced.
  • a nested set of overlapping deletion subclones were prepared by exonuclease III/nuclease SI digestion (Henikoff, S., 1986. Unidirectional digestion with exonuclease III created targeted breakpoints for DNA sequencing.
  • Orientation of Bam HI fragment 4 relative to Bam HI-15 was determined by partial sequencing of a Sal I- fragment containing the Bam HI-15 junction. Sequences obtained were compiled using the University of Wisconsin Genetics Computer Group software package (Devereux, J. , Haeberli, P. and Smithies, O. , 1984. A comprehensive set of sequence analysis for the VAX. Nucleic Acids Res. 12:387-395) in VAX/VMS version 7.1. It was found that the sequence contained two open reading frames.
  • a first ORF (SEQ ID NO:l), ORF-1, can be found from basepair no. 760 to basepair no. 2333.
  • the start codon is localized at basepair 2333, indicating a transcription direction opposite to the second ORF, ORF- 2, which can be found from basepair no. 2440 to basepair no. 2921.
  • the intergenic sequence between the two ORF's comprises an AT-rich sequence, which probably functions as a control element.
  • the non virulent PRV Bartha strain has 3 different lesions in its genome. Firstly a deletion in the US region influencing the expression of the glycoproteins gl and gp63 (Lo niczi et al. J.Virol. 49, 970-979 (1984)). Secondly a mutation in the nonessential gill glycoprotein (Mettenleiter et al. J.Virol. 62, 2712-2717 (1988)). Thirdly an effect in the BamHI-4 fragment that was not defined yet (Lominiczi et al., J.Virol. 61, 796-801 (1987)).
  • MOLECULE TYPE DNA (genomic)
  • ORGANISM Pseudorabies virus
  • ORGANISM Pseudorabies virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne la préparation d'un mutant du virus de la pseudorage formé par mutation dans la séquence d'acides nucléiques codant pour des polypeptides codés par la séquence d'acides nucléiques selon l'invention. Cette mutation empêche l'expression d'un ou de plusieurs de ces polypeptides. L'invention concerne également un mutant du virus de la pseudorage contenant un gène hétérologue codant un antigène d'un pathogène porcin incorporé à ladite séquence d'acides nucléiques. Un tel mutant du virus de la pseudorage peut être utilisé en tant que vaccin vecteur pour induire une réponse immunitaire après infection d'un animal hôte approprié. Le mutant du virus de la pseudorage permet également de faire la distinction entre des animaux infectés par le virus du vaccin et des animaux infectés par des virus produits naturellement.
EP93922915A 1992-10-06 1993-10-06 Vaccin contre la pseudorage Withdrawn EP0619840A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP93922915A EP0619840A1 (fr) 1992-10-06 1993-10-06 Vaccin contre la pseudorage

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP92203079 1992-10-06
EP92203079 1992-10-06
PCT/EP1993/002738 WO1994008000A1 (fr) 1992-10-06 1993-10-06 Vaccin contre la pseudorage
EP93922915A EP0619840A1 (fr) 1992-10-06 1993-10-06 Vaccin contre la pseudorage

Publications (1)

Publication Number Publication Date
EP0619840A1 true EP0619840A1 (fr) 1994-10-19

Family

ID=8210950

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93922915A Withdrawn EP0619840A1 (fr) 1992-10-06 1993-10-06 Vaccin contre la pseudorage

Country Status (3)

Country Link
EP (1) EP0619840A1 (fr)
JP (1) JPH07502173A (fr)
WO (1) WO1994008000A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269414A1 (en) 2003-11-04 2007-11-22 Shinji Okano Method for Producing Gene Transferred Denritic Cells
JP6055165B2 (ja) 2008-11-14 2016-12-27 株式会社Ｉｄファーマ 樹状細胞の製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559384B2 (ja) * 1985-07-29 1996-12-04 ジ・アップジョン・カンパニ− ウイルスワクチン
US5037742A (en) * 1986-07-18 1991-08-06 E. I. Du Pont De Nemours And Company Pseudorabies virus recombinants and their use in the production of proteins
NL8902087A (nl) * 1989-08-17 1991-03-18 Stichting Tech Wetenschapp Niet-natuurlijk voorkomend pseudorabiesvirus en vaccins die dit bevatten.
US5240703A (en) * 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9408000A1 *

Also Published As

Publication number Publication date
WO1994008000A1 (fr) 1994-04-14
JPH07502173A (ja) 1995-03-09

Similar Documents

Publication Publication Date Title
EP0141458B1 (fr) Mutant de délétion d'un virus d'herpès et vaccin contenant ce virus
EP0606437B1 (fr) Vaccin d'herpesvirus vivant non excretable
EP0538341B1 (fr) Vaccin a base de glycoproteine de vhe-4 (virus d'herpes equin-4)
EP1100925B1 (fr) Virus herpetique equin attenue
US8017317B2 (en) gM-negative EHV-mutants
EP0576092B1 (fr) Vaccin recombinant du herpes virus félin
EP0486562B1 (fr) Virus mutant de la pseudorage et vaccins le contenant
Gong et al. A single point mutation of Ala-25 to Asp in the 14,000-Mr envelope protein of vaccinia virus induces a size change that leads to the small plaque size phenotype of the virus
EP0606452B1 (fr) Vaccins vecteurs d'herpesvirus felin recombine
US5738854A (en) Pseudorabies virus vaccine
EP0654089B1 (fr) Virus de l'herpes equin recombinant
US5674499A (en) Equine herpesvirus gene 15 mutants
EP0668355B1 (fr) Vaccin pour protéger des chevaux contre des infections du virus de l'herpes équin
EP0619840A1 (fr) Vaccin contre la pseudorage
EP0663403A1 (fr) Vaccins du type I de l'herpesvirus bovin
US5695765A (en) Mutant pseudorabies virus, and vaccines containing the same
JPH09267A (ja) チミジンキナーゼ遺伝子に変異を有する組換えネコヘルペスウイルス１型及びそれを含むワクチン
US5874280A (en) Vector vaccines of bovine herpesvirus I
MXPA01001175A (en) Attenuated equine herpesvirus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990419

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990831